Novavax Inc: for 2026 and 2027, We Expect to Reduce Our R&D and SG&a Expenses to About $350 Mln and About $250 Mln, Respectively

THOMSON REUTERS
19 May

Novavax Inc: for 2026 and 2027, We Expect to Reduce Our R&D and SG&a Expenses to About $350 Mln and About $250 Mln, Respectively

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10